Author

Tore K Kvien

FOUR SARS-COV-2 VACCINE DOSES OR HYBRID IMMUNITY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPIES. A PROSPECTIVE, OBSERVATIONAL COHORT STUDY
FOUR SARS-COV-2 VACCINE DOSES OR HYBRID IMMUNITY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPIES. A PROSPECTIVE, OBSERVATIONAL COHORT STUDY

Tore K Kvien  et al.

THE PERSISTENCE OF ANTI-SPIKE ANTIBODIES FOLLOWING TWO SARS-COV-2 VACCINES IN PATIENTS WITH INFLAMMATORY BOWEL- AND JOINT DISEASES ON IMMUNOSUPPRESSIVE THERAPY COMPARED TO HEALTHY CONTROLS – A PROSPECTIVE COHORT STUDY
THE PERSISTENCE OF ANTI-SPIKE ANTIBODIES FOLLOWING TWO SARS-COV-2 VACCINES IN PATIENTS WITH INFLAMMATORY BOWEL- AND JOINT DISEASES ON IMMUNOSUPPRESSIVE THERAPY COMPARED TO HEALTHY CONTROLS – A PROSPECTIVE COHORT STUDY

Tore K Kvien  et al.

COVID-19 OUTCOME AND ASSOCIATION TO ANTI-SPIKE ANTIBODY CONCENTRATIONS IN PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPY; A PROSPECTIVE COHORT STUDY
COVID-19 OUTCOME AND ASSOCIATION TO ANTI-SPIKE ANTIBODY CONCENTRATIONS IN PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPY; A PROSPECTIVE COHORT STUDY

Tore K Kvien  et al.

IMMUNOGENICITY AND SAFETY OF A THREE-DOSE SARS-COV-2 VACCINATION STRATEGY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPY
IMMUNOGENICITY AND SAFETY OF A THREE-DOSE SARS-COV-2 VACCINATION STRATEGY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPY

Tore K Kvien  et al.

PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; THE RANDOMIZED NOR-DRUM PART B CLINICAL TRIAL
PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; THE RANDOMIZED NOR-DRUM PART B CLINICAL TRIAL

Tore K Kvien  et al.

Item 1 - 5 / 5
1